Seminars in Nephrology
Volume 27, Issue 2 , Pages 182-194 , March 2007

Treating Hypertension in the Patient With Overt Diabetic Nephropathy

  • Edmund J. Lewis, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Edmund J. Lewis, MD, 1426 W. Washington Blvd, Chicago, IL 60607.

References 

  1. Kussman MJ, Goldstein HH, Gleason RE. The clinical course of diabetic nephropathy. JAMA. 1976;236:1861–1873
  2. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ. 1982;285:685–688
  3. Nyberg D, Blohme G, Norden G. Constant glomerular filtration rate in diabetic nephropathy. Acta Med Scand. 1986;219:67–72
  4. Parving HH, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces the rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;1:1175–1179
  5. Parving HH, Andersen AR, Smidt UM, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ. 1987;294:1443–1447
  6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317:703–713
  7. Lewis JB, Berl T, Bain RP, et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis. 1999;34:809–817
  8. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  9. Brenner B, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  10. Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin 2 receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16:3027–3037
  11. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1:581–584
  12. D’Agostino RB, Belanger AJ, Kannel WB, et al. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction (The Framingham Study). BMJ. 1991;303:385–389
  13. Cruikshank JM. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. BMJ. 1988;297:1227–1230
  14. Kaplan N. J-curve not burned off by HOT study (Hypertension Optimal Treatment). Lancet. 1998;351:1748–1749
  15. Cruickshank JM. The J curve lives. Lancet. 1992;339:187
  16. Samuelson O, Wilhelmsen L, Anderson OK, et al. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension (Results from the primary prevention trial in Goteborg, Sweden). JAMA. 1987;258:1768–1776
  17. Farnett L, Multrow CD, Linn WD, et al. The J-curve phenomenon and the treatment of hypertension (Is there a point beyond which pressure reduction is dangerous?). JAMA. 1991;265:489–495
  18. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med. 2006;144:884–893
  19. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease (The International Verapamil-Trandolapril Study (INVEST): a randomized control trial). JAMA. 2003;290:2805–2816
  20. Berl T, Hunsicker LG, Lewis JB Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138:542–549
  21. Berl T, Hunsicker LG, Lewis JB, et al. Collaborative Study Group Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol. 2005;16:2170–2179
  22. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy. Arch Intern Med. 2003;163:1555–1565
  23. Osher E, Greenmen Y, Tordjman K, et al. Attempted forced titration of blood pressure to <130/85 mmHg in type 2 diabetic hypertensive patients in clinical practice: the diastolic cost. J Clin Hypertens. 2006;8:29–34
  24. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45:281–287
  25. DeZeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309–2320
  26. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med. 1993;329:1456–1462
  27. Nelson RG, Bennett PH, Beck GJ, et al. Diabetic Renal Disease Study Group Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med. 1996;335:1636–1642
  28. Yokoyama H, Tomonaga O, Hirayama M, et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia. 1997;40:405–411
  29. Keane WF, Brenner BM, deZeeuw D, et al. RENAAL Study Investigators The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:1499–1507
  30. Rossing P, Hommel E, Smidt UM, et al. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes. 1993;42:715–719
  31. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systemic review. BMJ. 2004;329:828–832
  32. Strippoli GF, Craig MC, Schena FP, et al. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol. 2006;17:S153–S155
  33. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114:838–854
  34. Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation. 2006;114:855–860
  35. Casas JP, Chua W, Loukogeorgakis S. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systemic review and meta-analysis. Lancet. 2005;366:2026–2033
  36. The Antihypertensive and Lipid-Lowering Treating to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA. 2002;288:2981–2997
  37. Levey AS, Uhlig K. Which antihypertensive agents in chronic kidney disease?. Ann Intern Med. 2006;144:213–215
  38. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936–946
  39. Hollenberg NK. Omission of drug dose information [letter]. Arch Intern Med. 2006;166:368
  40. Rahman M, Pressel SL, Davis BR. Omission of drug information [letter]. Arch Intern Med. 2006;166:368–369
  41. Williams B. The renin-angiotensin system and cardiovascular disease: hope or hype?. J Renin Angiotensin Aldosterone Syst. 2006;1:142–146
  42. Svensson P, De Faire U, Sleight P, et al. Comparative effect of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 2001;28:E28–E32
  43. deZeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921–927
  44. Ibsen H, Olsen MH, Wacktell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients (Losartan Intervention for Endpoints Reduction in Hypertension Study). Hypertension. 2005;45:198–202
  45. Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68:1190–1198
  46. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type I receptor antagonists. Circulation. 2004;109:2492–2499
  47. Mogensen CE, Neldam S, Tikkanen I, et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440–1444
  48. Rossing K, Christensen PK, Jensen BR, et al. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care. 2002;25:95–100
  49. Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant. 2002;17:1019–1024
  50. Jacobsen P, Andersen S, Jensen BR, et al. Addictive effect of ACE inhibition and angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol. 2003;14:992–999
  51. Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003;63:1874–1880
  52. Rossing K, Jacobsen P, Pietraszek L, et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care. 2003;26:2268–2274
  53. Andersen NH, Poulsen PL, Knudsen ST, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care. 2005;28:273–277
  54. Hollenberg NK. Is there a pharmacologic basis for combination renin axis blockade. Kidney Int. 2005;68:2901–2903
  55. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829–2836
  56. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin JASN. 2006;1:940–951
  57. Jafar TH, Stark PC, Schmid CH, et al. AIPRD Study Group Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Ann Intern Med. 2003;139:244–253

PII: S0270-9295(07)00006-X

doi: 10.1016/j.semnephrol.2007.01.005

Seminars in Nephrology
Volume 27, Issue 2 , Pages 182-194 , March 2007

Article Tools

* Image Usage & Resolution